Improved antitumor effect of ionizing radiation in combination with rapamycin for treating nasopharyngeal carcinoma

Wang,Di; Gao,Lichen; Liu,Xueting; Yuan,Chuang; Wang,Guihua

doi:10.3892/ol.2017.6208

Improved antitumor effect of ionizing radiation in combination with rapamycin for treating nasopharyngeal carcinoma

Authors:
- Di Wang
- Lichen Gao
- Xueting Liu
- Chuang Yuan
- Guihua Wang
View Affiliations

Affiliations: Department of Oncology, Changsha Central Hospital, Changsha, Hunan 410004, P.R. China, Department of Pharmacy, Changsha Central Hospital, Changsha, Hunan 410004, P.R. China, Medical Research Center, Changsha Central Hospital, Changsha, Hunan 410004, P.R. China
Published online on: May 19, 2017 https://doi.org/10.3892/ol.2017.6208
Pages: 1105-1108

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study is to investigate if rapamycin is a radiosensitizer of nasopharyngeal carcinoma (NPC), and to identify which pathways are involved in radiation sensitization. In vitro, using untreated cells as the control, NPC cells were treated with rapamycin, ionizing radiation (IR) or both. Differences in the phosphorylation of ribosomal protein S6 and glycogen synthase kinase (GSK) 3β, expression of cyclin D1, clonogenic survival, number of phosphorylated histone subunit 2AX (γH2AX) foci, and cell cycle status between the study groups were compared. The results indicated that rapamycin alone decreased the phosphorylation of S6 and GSK3β, as well as the expression of cyclin D1, in NPC cells. Thus, rapamycin‑treated NPC cells had lower cell viability, and higher DNA damage and G1 arrest than control cells. In addition, the combination of rapamycin and IR caused the highest cell death, DNA damage and G1 arrest when compared with the effects caused by either treatment alone. In conclusion, rapamycin improves the anti‑tumor effect of IR for treating NPC through inhibiting the Akt/mechanistic target of rapamycin/S6 and Akt/GSK3β/cyclin D1 signaling pathways.

View Figures

View References

1	Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS and Leong CO: Suppression of BCL-2 synergizes cisplatin sensitivity in nasopharyngeal carcinoma cells. Cancer Lett. 314:166–175. 2012. View Article : Google Scholar : PubMed/NCBI
2	Lee AW, Lin JC and Ng WT: Current management of nasopharyngeal cancer. Semin Radiat Oncol. 22:233–244. 2012. View Article : Google Scholar : PubMed/NCBI
3	Yoshizaki T, Ito M, Murono S, Wakisaka N, Kondo S and Endo K: Current understanding and management of nasopharyngeal carcinoma. Auris Nasus Larynx. 39:137–144. 2012. View Article : Google Scholar : PubMed/NCBI
4	Orlandi E, Tomatis S, Potepan P, Bossi P, Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C, Locati L, et al: Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma. Future Oncol. 9:103–114. 2013. View Article : Google Scholar : PubMed/NCBI
5	Bussink J, van der Kogel AJ and Kaanders JH: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 9:288–296. 2008. View Article : Google Scholar : PubMed/NCBI
6	Shimura T: Acquired radioresistance of cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat Res. 52:539–544. 2011. View Article : Google Scholar : PubMed/NCBI
7	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
8	Liu Y, Chen LH, Yuan YW, Li QS, Sun AM and Guan J: Activation of AKT is associated with metastasis of nasopharyngeal carcinoma. Tumour Biol. 33:241–245. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li HF, Kim JS and Waldman T: Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol. 4:432009. View Article : Google Scholar : PubMed/NCBI
10	Xia S, Zhao Y, Yu S and Zhang M: Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells. Cancer Biother Radiopharm. 25:317–323. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zhang HH, Lipovsky AI, Dibble CC, Sahin M and Manning BD: S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell. 24:185–197. 2006. View Article : Google Scholar : PubMed/NCBI
12	Albert JM, Kim KW, Cao C and Lu B: Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther. 5:1183–1189. 2006. View Article : Google Scholar : PubMed/NCBI
13	Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE and Lu B: Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene. 24:5414–5422. 2005. View Article : Google Scholar : PubMed/NCBI
14	Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ and Lu B: Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 66:10040–10047. 2006. View Article : Google Scholar : PubMed/NCBI
15	Nassim R, Mansure JJ, Chevalier S, Cury F and Kassouf W: Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: A novel strategy for treatment. PLoS One. 8:e652572013. View Article : Google Scholar : PubMed/NCBI
16	Abraham RT and Wiederrecht GJ: Immunopharmacology of rapamycin. Annu Rev Immunol. 14:483–510. 1996. View Article : Google Scholar : PubMed/NCBI
17	Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S and Bernhard EJ: Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res. 68:5915–5923. 2008. View Article : Google Scholar : PubMed/NCBI
18	Suárez C, Rodrigo JP, Rinaldo A, Langendijk JA, Shaha AR and Ferlito A: Current treatment options for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol. 267:1811–1824. 2010. View Article : Google Scholar : PubMed/NCBI
19	LoPiccolo J, Blumenthal GM, Bernstein WB and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations. Drug Resist Updat. 11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kim MK, Kim TJ, Sung CO, Choi CH, Lee JW, Kim BG and Bae DS: High expression of mTOR is associated with radiation resistance in cervical cancer. J Gynecol Oncol. 21:181–185. 2010. View Article : Google Scholar : PubMed/NCBI
21	Romano G: The role of the dysfunctional akt-related pathway in cancer: Establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development. Scientifica (Cairo). 2013:3171862013.PubMed/NCBI
22	Liu SC, Tsang NM, Chiang WC, Chang KP, Hsueh C, Liang Y, Juang JL, Chow KP and Chang YS: Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J Clin Invest. 123:5269–5283. 2013. View Article : Google Scholar : PubMed/NCBI
23	Chung J, Kuo CJ, Crabtree GR and Blenis J: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 69:1227–1236. 1992. View Article : Google Scholar : PubMed/NCBI
24	Terada N, Takase K, Papst P, Nairn AC and Gelfand EW: Rapamycin inhibits ribosomal protein synthesis and induces G1 prolongation in mitogen-activated T lymphocytes. J Immunol. 155:3418–3426. 1995.PubMed/NCBI
25	Baldin V, Lukas J, Marcote MJ, Pagano M and Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
26	Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, et al: A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 474:230–234. 2011. View Article : Google Scholar : PubMed/NCBI
27	Shimura T, Fukumoto M and Kunugita N: The role of cyclin D1 in response to long-term exposure to ionizing radiation. Cell Cycle. 12:2738–2743. 2013. View Article : Google Scholar : PubMed/NCBI
28	Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
29	Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, Shen R, Korte S, Lisa D, Ganly I, et al: A phase I study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 87:479–486. 2013. View Article : Google Scholar : PubMed/NCBI